1. Cell Cycle/DNA Damage
  2. Polo-like Kinase (PLK)

Polo-like Kinase (PLK)

Polo-like Kinases (PLKs) are important regulators of the cell cycle. Plks are involved in the formation of and the changes in the mitotic spindle and in the activation of CDK/cyclin complexes during M-phase of the cell cycle.Polo-like kinases (Plks) are a family of conserved serine/threonine kinases involved in the regulation of cell cycle progression through G2 and mitosis. Mammalian polo-like kinases include Plk1 (Xenopus Plx1), Plk2/Snk (Xenopus Plx2), Plk3/Prk/FnK (Xenopus Plx3), Plk4/Sak and Plk5. Plk1 is involved in the regulation of key steps during cell division, DNA damage repair pathways, apoptosis, and the progression of the cell cycle. Plk3 is a multifunctional stress response protein that responses to signals induced by DNA damage and/or mitotic spindle disruption.

Polo-like Kinase (PLK) Related Products (23):

Cat. No. Product Name Effect Purity
  • HY-12137
    Volasertib Inhibitor 98.76%
    Volasertib is a highly potent PLK1 inhibitor with an IC50 of 0.87 nM, as well as the two closely related kinases Plk2 and Plk3 with IC50 values of 5 and 56 nM, respectively.
  • HY-50698
    BI 2536 Inhibitor 99.95%
    BI 2536 is a potent and selective inhibitor of Plk1 with IC50 of 0.83 nM, and is also a potent inhibitor of BRD4 with IC50 of 25 nM.
  • HY-18682
    Centrinone Inhibitor 98.02%
    Centrinone is a selective and reversible inhibitor of polo-like kinase 4 (PlK4) with a Ki of 0.16 nM.
  • HY-12037
    Rigosertib sodium Inhibitor 98.55%
    Rigosertib (sodium) is a non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM, and shows 30-fold greater selectivity against PLK2.
  • HY-18683
    Centrinone-B Inhibitor 98.58%
    Centrinone-B is a potent and highly selective PLK4 inhibitor, with a Ki of 0.59 nM.
  • HY-15828
    NMS-1286937 Inhibitor 99.32%
    NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with IC50 of 2 nM.
  • HY-11003
    GW843682X Inhibitor 99.75%
    GW843682X is a selective, ATP-competitive inhibitor of PLK1 and PLK3, with IC50s of 2.2 nM and 9.1 nM, respectively, and is also >100-fold selective against ∼30 other kinases.
  • HY-50877
    GSK461364 Inhibitor 99.82%
    GSK461364 is a potent, selective, reversible, ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM.
  • HY-12300
    CFI-400945 free base Inhibitor 98.45%
    CFI-400945 free base is a potent, selective and orally bioavailable PLK4 inhibitor with a Ki and an IC50 of 0.26 nM and 2.8 nM, respectively.
  • HY-15160
    TAK-960 Inhibitor
    TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM at 10 μM ATP; TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively.
  • HY-18009
    LFM-A13 Inhibitor 99.70%
    LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.
  • HY-15161
    Ro3280 Inhibitor 99.85%
    Ro3280 is a potent, highly selective inhibitor of PLK1 with an IC50 and a Kd of 3 nM and 0.09 nM, respectively, and nearly has no effect on PLK2 and PLK3.
  • HY-12300B
    CFI-400945 fumarate Inhibitor 99.27%
    CFI-400945 fumarate is a potent, selective and orally bioavailable PLK4 inhibitor with a Ki and an IC50 of 0.26 nM and 2.8 nM, respectively.
  • HY-12134
    Poloxin Inhibitor
    Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain, with an IC50 of appr 4.8 μM.
  • HY-12045
    HMN-214 Inhibitor 99.25%
    HMN-214, an orally bioavailable prodrug of HMN-176, is an inhibitor of polo-like kinase-1 (plk1), with antitumor activity.
  • HY-15160B
    TAK-960 dihydrochloride Inhibitor 99.80%
    TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM at 10 μM ATP; TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively.
  • HY-15155
    MLN0905 Inhibitor
    MLN0905 is a potent PLK1 inhibitor, with an IC50 of 2 nM.
  • HY-15158
    SBE13 Hydrochloride Inhibitor 98.61%
    SBE13 Hydrochloride is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC50>66 μM) or Plk3 (IC50=875 nM).
  • HY-13994
    Mps1-IN-2 Inhibitor 98.06%
    Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor, with an IC50 and a Kd of 145 nM and 12 nM for Mps1 and a Kd of 61 nM for Plk1.
  • HY-15158A
    SBE13 Inhibitor
    SBE13 is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE13 poorly inhibits Plk2 (IC50>66 μM) or Plk3 (IC50=875 nM).
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.